Asston Pharmaceuticals IPO

Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally. The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more. The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers. The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing. Products: Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections. Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever. Ferrovit Syrup: To treat vitamin and mineral deficiencies. As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments. Competitive Strengths: Formulation Expertise Experienced Promoters Wide range of Products Strategic Location Skilled Workforce

The Company Asston Pharmaceuticals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects: S.No. Objects of the Issue Expected Amount (in Million) 1 Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit 60 2 Funding the incremental working capital requirements of the Company 130 3 Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company 10 4 General Corporate Purposes

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App